ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Videm, V.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Videm, V.
Related Collections
Right arrow Molecular biology

Ann Thorac Surg 2004;77:456-457
© 2004 The Society of Thoracic Surgeons

Invited commentary

Vibeke Videm, MD, PhD

Department of Immunology and Transfusion Medicine, Institute of Laboratory Medicine, Children's and Women's Health, Trondheim University Hospital, Norwegian University of Science and Technology, N-7006 Trondheim, Norway

e-mail: vibeke.videm@medisin.ntnu.no

The first 20% of the full text of this article appears below.

Pulmonary hypertension is a debilitating disease associated with disparate factors, ranging from pulmonary disorders, thromboembolism, and familial genetic aberrations to the use of appetite suppressants. The exact mechanisms of the disease remain unknown, and might vary for different forms. A more general hypothesis is evolving, however, and the present paper by Dr Chu and coworkers from Dr Thistlethwaite's group provides significant support for it.

The vascular endothelial growth factor (VEGF) family and angiopoietin family of . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2004 by The Society of Thoracic Surgeons.